middle.news
Prescient Therapeutics Launches $7 Million SPP to Propel PTX-100 Development
8:57am on Wednesday 26th of August, 2026 AEST
•
Healthcare
Read Story
Prescient Therapeutics Launches $7 Million SPP to Propel PTX-100 Development
8:57am on Wednesday 26th of August, 2026 AEST
Key Points
SPP priced at $0.065 per share, 18.8% discount to 10-day VWAP
Funds targeted to progress PTX-100 past key 2026 clinical milestone
Eligible shareholders can invest up to $30,000 without brokerage
Potential follow-on placement to sophisticated investors post-SPP
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE